Elomia Review 2026: AI Therapy Chatbot for Individuals and Employers

Quick Verdict

Elomia is a credible second-generation AI therapy chatbot that aims for more natural conversation than rule-based predecessors like older versions of Wysa or Woebot. It draws on CBT principles and offers both consumer subscriptions and B2B employer access. However, it lacks the deep peer-reviewed clinical validation of Wysa (30+ publications) or Woebot before its 2025 shutdown (14+ RCTs). For users who simply want a conversational AI mental health companion, Elomia is reasonable. For users who specifically need clinical validation, Wysa remains the stronger choice.

What Elomia Does

Elomia provides a conversational chatbot interface where users can talk through anxiety, stress, low mood, relationship difficulties, work pressure, and everyday emotional challenges. Conversations are private, available 24/7, and grounded in CBT-style techniques such as thought reframing, behavioral activation, gratitude practice, and grounding exercises. The platform uses modern large language model technology to make conversations feel more natural than older script-driven chatbots.

Key Features

• AI chatbot with CBT-informed conversation patterns
• 24/7 anonymous support — no scheduling, no waitlists
• Mood tracking and check-ins
• Crisis detection and routing to emergency resources
• Self-help exercises for anxiety, depression, sleep, and stress
• B2B employer dashboards for wellness program reporting (de-identified)
• Mobile-friendly, no clinician account required

Pricing

Elomia offers a free trial and consumer subscriptions in the typical $10-15/month range, with annual and lifetime options. Employer pricing is per-employee-per-month (PEPM) and negotiated by contract. Exact list pricing varies and is best verified on the Elomia site.

Clinical Evidence

Elomia has published some pilot data and user-reported outcome surveys, but it does not have a portfolio of peer-reviewed randomized controlled trials. This is a meaningful gap relative to Wysa and the now-discontinued Woebot. Users seeking the strongest clinical evidence base should consider Wysa first.

HIPAA Compliance & Data Security

Elomia operates primarily as a consumer-facing AI companion with a B2B/employer deployment option. For the B2B deployment — where US-based employers may be subject to HIPAA if the product is offered through a covered health plan or EAP — HIPAA compliance becomes relevant. Here's what we verified:

• Business Associate Agreement (BAA): May require Enterprise tier. Smaller startups like Elomia typically do not offer a BAA by default on consumer plans. Employers considering B2B deployments should explicitly request a BAA during contracting.
• Encryption: Standard AES-256 at rest and TLS 1.2+ in transit assumed for HIPAA-eligible vendors; verify directly.
• SOC 2 Certification: Elomia has not publicly published a SOC 2 Type II attestation. Enterprise buyers should request current attestation documentation directly.
• Data Residency: Consumer deployment is global; B2B US deployments typically use US-based cloud infrastructure.
• Session Recording Handling: Elomia is chat-based rather than audio-based. Conversation logs are the primary data artifact; retention and purge controls should be confirmed contractually.
• Key consideration: Elomia is a consumer-first product. B2B and HIPAA posture are available but not the default. Do not assume consumer-tier protections meet HIPAA standards without explicit written confirmation.

What clinicians (or employer buyers) should verify before signing up:

1. Request a current BAA template before sharing any PHI
2. Confirm SOC 2 Type II attestation date (should be within last 12 months)
3. Document data retention and deletion policies in your practice's privacy policy
4. Confirm whether AI training uses your client data (most tools now offer opt-out)

Important disclaimer: This information reflects publicly available compliance posture. Always verify current BAA terms, certifications, and data handling directly with the vendor before processing any PHI through their system.

Weaknesses and Limitations

• Limited published research: No major peer-reviewed RCTs comparable to Wysa or Woebot
• Smaller user base: Less user reviews available than Wysa or Replika
• Not a therapy replacement: Cannot diagnose or treat mental health conditions
• LLM safety concerns: Like all LLM chatbots, there is a real risk that the model occasionally produces unhelpful or inappropriate responses; crisis routing reduces but does not eliminate this risk

Who Elomia Is Best For

• Individuals wanting an AI mental health companion that feels conversational rather than scripted
• Employees whose company offers Elomia as a benefit
• People seeking 24/7 anonymous support for everyday stress and mood challenges
• Users for whom clinical research depth is less important than conversational quality

Who Should Look Elsewhere

• Anyone in acute crisis — call 988 or text HOME to 741741
• People seeking the most clinically validated app — Wysa has more research
• People needing diagnosis or prescription — see Talkiatry or a licensed clinician

Bottom Line

Elomia is a competent dual-market AI therapy chatbot. Its conversational quality is its main selling point, and its B2B distribution through employers gives it reach. For individuals choosing between consumer AI mental health apps in 2026, Wysa remains the stronger pick on clinical evidence, but Elomia is a reasonable option for those who prefer a more naturalistic chat experience or whose employer already offers it.